Technical Analysis for ALRN - Aileron Therapeutics, Inc.
|Grade||Last Price||% Change||Price Change|
ALRN closed down 10.31 percent on Friday, September 21, 2018, on 62 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
|See historical ALRN trend table...|
|Date||Alert Name||Type||% Chg|
|Sep 21||Fell Below 20 DMA||Bearish||0.00%|
|Sep 21||Fell Below 50 DMA||Bearish||0.00%|
|Sep 21||Wide Bands||Range Expansion||0.00%|
|Sep 20||50 DMA Support||Bullish||-10.31%|
|Sep 20||Inside Day||Range Contraction||-10.31%|
|Sep 20||Wide Bands||Range Expansion||-10.31%|
|Sep 19||50 DMA Support||Bullish||-15.34%|
|Sep 19||MACD Bullish Centerline Cross||Bullish||-15.34%|
|Sep 19||Pocket Pivot||Bullish Swing Setup||-15.34%|
|Sep 19||Doji - Bearish?||Reversal||-15.34%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Aileron Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing a class of therapeutics called stapled peptides. It is also developing a pipeline of stapled peptide drugs across a range of therapeutic areas, including cancer, endocrine and metabolic diseases and inflammation. The Company is advancing its lead oncology program to deliver efficacy and safety in a spectrum of solid and hematological malignancies. Its lead product candidate, ALRN-6924, targets the tumor suppressor protein p53 for the treatment of a range of cancers. The Company is conducting an ongoing Phase I clinical trial of ALRN-6924 in adult patients with solid tumors or lymphomas expressing non-mutated or wild-type p53 that are refractory to or intolerant of standard therapy. ALRN-6924 may reactivate p53-mediated cell death by targeting both of the natural p53 suppressor proteins, Mouse double minute 2 homolog (MDM2) and MDMX.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more ALRN news...
|52 Week High||15.48|
|52 Week Low||1.98|
|200-Day Moving Average||6.3651|
|50-Day Moving Average||3.1112|
|20-Day Moving Average||2.9965|
|10-Day Moving Average||3.012|
|Average True Range||0.3952|
|Chandelier Exit (Long, 3 ATRs )||2.9144|
|Chandelier Exit (Short, 3 ATRs )||3.2756|
|Upper Bollinger Band||3.8386|
|Lower Bollinger Band||2.1544|
|Percent B (%b)||0.42|
|MACD Signal Line||-0.0107|
|Market Cap||42.23 Million|
|Num Shares||14.7 Million|
|Price-to-Earnings (P/E) Ratio||-0.07|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||3.61|
|Resistance 3 (R3)||3.69||3.52||3.48|
|Resistance 2 (R2)||3.52||3.34||3.48||3.44|
|Resistance 1 (R1)||3.20||3.22||3.12||3.12||3.40|
|Support 1 (S1)||2.71||2.85||2.63||2.63||2.34|
|Support 2 (S2)||2.54||2.73||2.50||2.30|
|Support 3 (S3)||2.22||2.54||2.26|
|Support 4 (S4)||2.14|